{"transactions":[{"id":1175317,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2025-04-08T17:01:33.000Z","date":"2025-04-07","kind":"sale","planned":false,"acquired":false,"shares":3678,"price":4.5513,"value":16739.6814,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $4.55 to $4.57. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":89868,"source":{"system":"sec-edgar","filing":"0000950170-25-052156","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017025052156/ownership.xml","form_type":"4"}},{"id":1235370,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-03T17:15:30.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":50000,"derivative":{"exercise_price":5.76,"expiration_date":"2035-02-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-031042","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017025031042/ownership.xml","form_type":"4"}},{"id":1235369,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2025-03-03T17:15:30.000Z","date":"2025-02-27","kind":"grant","planned":false,"acquired":true,"shares":72000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on February 27, 2025. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of February 27, 2025, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":165546,"source":{"system":"sec-edgar","filing":"0000950170-25-031042","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017025031042/ownership.xml","form_type":"4"}},{"id":1296234,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2025-01-23T16:24:08.000Z","date":"2025-01-21","kind":"sale","planned":false,"acquired":false,"shares":6583,"price":6.5883,"value":43370.7789,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices $6.5855 to $6.6519. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the \"Company\"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,973 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2025."}],"balance_after":93546,"source":{"system":"sec-edgar","filing":"0000950170-25-008357","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017025008357/ownership.xml","form_type":"4"}},{"id":1323933,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2024-12-20T16:20:21.000Z","date":"2024-12-19","kind":"sale","planned":false,"acquired":false,"shares":1291,"price":8,"value":10328.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."}],"balance_after":98156,"source":{"system":"sec-edgar","filing":"0000950170-24-139062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017024139062/ownership.xml","form_type":"4"}},{"id":1452359,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2024-07-17T14:51:21.000Z","date":"2024-07-15","kind":"sale","planned":false,"acquired":false,"shares":4325,"price":11.72,"value":50689.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,009 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024."}],"balance_after":99447,"source":{"system":"sec-edgar","filing":"0000950170-24-084182","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017024084182/ownership.xml","form_type":"4"}},{"id":1496382,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stoock","published_at":"2024-05-31T18:37:55.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 31, 2024. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of December 18, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":102763,"source":{"system":"sec-edgar","filing":"0000950170-24-067548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017024067548/ownership.xml","form_type":"4"}},{"id":1543618,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stoock","published_at":"2024-04-10T16:30:09.000Z","date":"2024-04-08","kind":"sale","planned":false,"acquired":false,"shares":3435,"price":11.1,"value":38128.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."}],"balance_after":95263,"source":{"system":"sec-edgar","filing":"0000950170-24-043385","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000095017024043385/ownership.xml","form_type":"4"}},{"id":1674047,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-22T20:22:31.000Z","date":"2024-01-18","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest with respect to 25% of the shares of common stock on January 18, 2025, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":120000,"derivative":{"exercise_price":7.6,"expiration_date":"2034-01-17","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001209191-24-002021","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919124002021/doc4.xml","form_type":"4"}},{"id":1674046,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2024-01-22T20:22:31.000Z","date":"2024-01-19","kind":"sale","planned":false,"acquired":false,"shares":6307,"price":7.7533,"value":48900.0631,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,944 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2024."}],"balance_after":98698,"source":{"system":"sec-edgar","filing":"0001209191-24-002021","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919124002021/doc4.xml","form_type":"4"}},{"id":1732365,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-11-21T16:40:36.000Z","date":"2023-11-20","kind":"sale","planned":false,"acquired":false,"shares":2127,"price":7.2415,"value":15402.6705,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices between $7.24 and $7.2893. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":103061,"source":{"system":"sec-edgar","filing":"0001209191-23-056288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123056288/doc4.xml","form_type":"4"}},{"id":1749464,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-11-03T16:55:17.000Z","date":"2023-11-01","kind":"sale","planned":false,"acquired":false,"shares":11681,"price":8.95,"value":104544.95,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of performance stock units."}],"balance_after":105188,"source":{"system":"sec-edgar","filing":"0001209191-23-054355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123054355/doc4.xml","form_type":"4"}},{"id":1749463,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-11-03T16:55:17.000Z","date":"2023-11-01","kind":"sale","planned":false,"acquired":false,"shares":811,"price":7.8,"value":6325.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of performance stock units."}],"balance_after":116869,"source":{"system":"sec-edgar","filing":"0001209191-23-054355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123054355/doc4.xml","form_type":"4"}},{"id":1749462,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-11-03T16:55:17.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares earned with respect to a performance stock unit award granted on January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023."}],"balance_after":117680,"source":{"system":"sec-edgar","filing":"0001209191-23-054355","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123054355/doc4.xml","form_type":"4"}},{"id":1824696,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-07-21T20:30:08.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This amendment is being filed to correct the transaction price included in the Form 4 filed on behalf of the Reporting Person on July 17, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023."}],"balance_after":95180,"source":{"system":"sec-edgar","filing":"0001209191-23-043162","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123043162/doc4a.xml","form_type":"4/A","original_submission_date":"2023-07-17"}},{"id":1828521,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-07-17T17:00:16.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":1,"value":25000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on July 14, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of July 14, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,674 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2023."}],"balance_after":95180,"source":{"system":"sec-edgar","filing":"0001209191-23-042455","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123042455/doc4.xml","form_type":"4"}},{"id":1866468,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-06-05T18:32:58.000Z","date":"2023-06-02","kind":"sale","planned":true,"acquired":false,"shares":1960,"price":11.4121,"value":22367.716,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 11.41 and 11.5653. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":68506,"source":{"system":"sec-edgar","filing":"0001209191-23-034605","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123034605/doc4.xml","form_type":"4"}},{"id":1880822,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-05-23T12:15:04.000Z","date":"2023-05-22","kind":"sale","planned":true,"acquired":false,"shares":2110,"price":12.8744,"value":27164.984,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in two transactions at prices 12.87 and 13.06. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":70466,"source":{"system":"sec-edgar","filing":"0001209191-23-031647","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123031647/doc4.xml","form_type":"4"}},{"id":1922874,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-04-07T15:18:03.000Z","date":"2023-04-06","kind":"sale","planned":true,"acquired":false,"shares":3439,"price":7.27,"value":25001.53,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units."}],"balance_after":72576,"source":{"system":"sec-edgar","filing":"0001209191-23-023749","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123023749/doc4.xml","form_type":"4"}},{"id":1972235,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-03-03T19:03:31.000Z","date":"2023-03-01","kind":"sale","acquired":false,"shares":2032,"price":8.5309,"value":17334.7888,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 28, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.3385 to $8.5524. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":76015,"source":{"system":"sec-edgar","filing":"0001209191-23-016023","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123016023/doc4.xml","form_type":"4"}},{"id":2049471,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-20T19:32:25.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option will vest with respect to 25% of the shares of common stock on January 19, 2024, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":55000,"derivative":{"exercise_price":8.35,"expiration_date":"2033-01-18","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-23-004337","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123004337/doc4.xml","form_type":"4"}},{"id":2049470,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2023-01-20T19:32:25.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":33000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on January 19, 2023. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of January 19, 2023, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,706 shares acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in January 2023."}],"balance_after":78047,"source":{"system":"sec-edgar","filing":"0001209191-23-004337","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919123004337/doc4.xml","form_type":"4"}},{"id":2104973,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2022-11-23T16:10:31.000Z","date":"2022-11-21","kind":"sale","acquired":false,"shares":2159,"price":9.6,"value":20726.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.59 to $9.8716. The reporting person undertakes to provide the Issuer, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":43341,"source":{"system":"sec-edgar","filing":"0001209191-22-058627","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122058627/doc4.xml","form_type":"4"}},{"id":2167206,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2022-09-02T16:05:32.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on September 1, 2022. Fifty percent (50%) of the total number of RSUs granted vest on each of March 1, 2023 and June 1, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":45500,"source":{"system":"sec-edgar","filing":"0001209191-22-048473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122048473/doc4.xml","form_type":"4"}},{"id":2261498,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2022-05-20T17:17:04.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on May 19, 2022. One third (1/3) of the total number of RSUs granted vest on November 19, 2022, May 19, 2023 and November 19, 2023, subject to the Reporting Person's continued service on each applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001209191-22-031085","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122031085/doc4.xml","form_type":"4"}},{"id":2269908,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2022-05-16T20:43:32.000Z","date":"2022-05-13","kind":"purchase","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.50 to $7.90. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":26000,"source":{"system":"sec-edgar","filing":"0001209191-22-029446","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122029446/doc4.xml","form_type":"4"}},{"id":2302302,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-04-06T20:50:18.000Z","date":"2022-04-05","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest with respect to 25% of the shares of common stock on April 5, 2023, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates."}],"balance_after":100000,"derivative":{"exercise_price":15.08,"expiration_date":"2032-04-04","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-22-023561","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122023561/doc4.xml","form_type":"4"}},{"id":2302301,"issuer":{"id":5177,"kind":"organization","name":"Phathom Pharmaceuticals, Inc.","symbol":"PHAT"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO and CBO"}}],"security":"Common Stock","published_at":"2022-04-06T20:50:18.000Z","date":"2022-04-05","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on April 5, 2022. One third (1/3) of the total number of RSUs granted vest on each of the first three anniversaries of April 5, 2022, the vesting commencement date, subject to the Reporting Person's continued service on the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-22-023561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1363812/000120919122023561/doc4.xml","form_type":"4"}},{"id":2416700,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-02-02T21:34:38.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025."}],"balance_after":30000,"derivative":{"exercise_price":7.72,"expiration_date":"2032-01-31","underlying":"Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-22-006385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919122006385/doc4.xml","form_type":"4"}},{"id":2416699,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-02T21:34:38.000Z","date":"2022-01-31","kind":"grant","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025."}],"balance_after":7500,"derivative":{"underlying":"Ordinary Shares","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-22-006385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919122006385/doc4.xml","form_type":"4"}},{"id":2416698,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2022-02-02T21:34:38.000Z","date":"2022-01-31","kind":"exercise","acquired":false,"shares":666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The reporting person was granted RSUs on January 31, 2021 representing 2,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022."}],"balance_after":1334,"derivative":{"underlying":"Ordinary Shares","underlying_shares":1334},"source":{"system":"sec-edgar","filing":"0001209191-22-006385","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919122006385/doc4.xml","form_type":"4"}},{"id":2416697,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:34:38.000Z","date":"2022-01-31","kind":"sale","acquired":false,"shares":331,"price":7.58,"value":2508.98,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units"}],"balance_after":5248,"source":{"system":"sec-edgar","filing":"0001209191-22-006385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919122006385/doc4.xml","form_type":"4"}},{"id":2416696,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2022-02-02T21:34:38.000Z","date":"2022-01-31","kind":"exercise","acquired":true,"shares":666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":5579,"source":{"system":"sec-edgar","filing":"0001209191-22-006385","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919122006385/doc4.xml","form_type":"4"}},{"id":2488763,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-02T18:15:17.000Z","date":"2021-11-30","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023."}],"balance_after":10000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-067439","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121067439/doc4.xml","form_type":"4"}},{"id":2488762,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-02T18:15:17.000Z","date":"2021-11-30","kind":"sale","acquired":false,"shares":2587,"price":12.03,"value":31121.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units"}],"balance_after":4913,"source":{"system":"sec-edgar","filing":"0001209191-21-067439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121067439/doc4.xml","form_type":"4"}},{"id":2488761,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Ordinary Shares","published_at":"2021-12-02T18:15:17.000Z","date":"2021-11-30","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one ordinary share of the Issuer"}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-21-067439","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121067439/doc4.xml","form_type":"4"}},{"id":2677605,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-08T18:33:00.000Z","date":"2021-06-05","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares underlying the stock options will vest on each of June 1, 2022, June 1, 2023 and June 1, 2024."}],"balance_after":15000,"derivative":{"exercise_price":17.98,"expiration_date":"2031-05-31","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-21-038841","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121038841/doc4.xml","form_type":"4"}},{"id":2708154,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-05-18T15:36:39.000Z","date":"2021-05-17","kind":"purchase","acquired":true,"shares":2500,"price":15.85,"value":39625.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0001209191-21-033402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121033402/doc4.xml","form_type":"4"}},{"id":2885720,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-02-02T20:57:06.000Z","date":"2021-01-31","kind":"grant","acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024."}],"balance_after":2000,"derivative":{"underlying":"Ordinary Shares","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-21-006710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121006710/doc4.xml","form_type":"4"}},{"id":2885719,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-02T20:57:06.000Z","date":"2021-01-31","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares underlying the stock option will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024."}],"balance_after":6000,"derivative":{"exercise_price":22.07,"expiration_date":"2031-01-30","underlying":"Ordinary Shares","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-21-006710","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919121006710/doc4.xml","form_type":"4"}},{"id":3013350,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-10-05T20:37:11.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3 of the shares underlying the restricted stock units will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"1/3 of the shares underlying the restricted stock units will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-20-053641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120053641/doc4.xml","form_type":"4"}},{"id":3013349,"issuer":{"id":4466,"kind":"organization","name":"UroGen Pharma Ltd.","symbol":"URGN"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-05T20:37:11.000Z","date":"2020-10-01","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares underlying the stock options will vest on each of October 1, 2021, October 1, 2022 and October 1, 2023."}],"balance_after":60000,"derivative":{"exercise_price":19.66,"expiration_date":"2030-09-30","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-20-053641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1668243/000120919120053641/doc4.xml","form_type":"4"}},{"id":3161717,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Options","published_at":"2020-05-05T16:00:45.000Z","date":"2020-05-04","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023."}],"balance_after":50000,"derivative":{"exercise_price":0.66,"expiration_date":"2030-05-04","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001493152-20-007732","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315220007732/ownership.xml","form_type":"4"}},{"id":3388024,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Option","published_at":"2019-10-25T16:30:50.000Z","date":"2019-10-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2019 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on October 24, 2020, one-third on October 24, 2021, and will be fully vested on October 24, 2022."}],"balance_after":25000,"derivative":{"exercise_price":0.31,"exercise_date":"2020-10-24","expiration_date":"2029-10-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001493152-19-016008","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315219016008/ownership.xml","form_type":"4"}},{"id":3557847,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Common Stock","published_at":"2019-04-11T12:11:06.000Z","date":"2019-04-11","kind":"grant","acquired":true,"shares":2500,"price":3.6799,"value":9199.75,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a voluntary at market stock purchase by the reporting person on the open market."}],"balance_after":5833,"source":{"system":"sec-edgar","filing":"0001493152-19-005147","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315219005147/ownership.xml","form_type":"4"}},{"id":3558642,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Common Stock","published_at":"2019-04-10T09:12:01.000Z","date":"2019-04-09","kind":"grant","acquired":true,"shares":100,"price":3.85,"value":385.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a voluntary at market stock purchase by the reporting person on the open market."}],"balance_after":100,"source":{"system":"sec-edgar","filing":"0001493152-19-005083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315219005083/ownership.xml","form_type":"4"}},{"id":3558641,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Common Stock","published_at":"2019-04-10T09:12:01.000Z","date":"2019-04-09","kind":"grant","acquired":true,"shares":2900,"price":3.8599,"value":11193.71,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a voluntary at market stock purchase by the reporting person on the open market."}],"balance_after":2900,"source":{"system":"sec-edgar","filing":"0001493152-19-005083","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315219005083/ownership.xml","form_type":"4"}},{"id":3771717,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Option","published_at":"2018-11-07T17:00:30.000Z","date":"2018-11-05","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This award relates to the annual long term incentive grant awarded by the Compensation Committee following the completion of our 2018 Fiscal Year and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on November 5, 2019, one-third on November 5, 2020, and will be fully vested on November 5, 2021."}],"balance_after":125000,"derivative":{"exercise_price":0.54,"exercise_date":"2019-11-05","expiration_date":"2018-11-05","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001493152-18-015367","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315218015367/form4.xml","form_type":"4"}},{"id":3895694,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Common Stock","published_at":"2018-06-13T18:37:35.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":5000,"price":1.89,"value":9450.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a voluntary at market stock purchase by the reporting person on the open market."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0001493152-18-008632","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315218008632/form4.xml","form_type":"4"}},{"id":3900296,"issuer":{"id":93434,"kind":"organization","name":"Ayala Pharmaceuticals, Inc.","symbol":"ADXS"},"owners":[{"id":80954,"kind":"person","name":"Henderson Molly","position":1,"cik":"0001363812","reported_name":"Henderson Molly","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Vice President & CFO"}}],"security":"Stock Option","published_at":"2018-06-08T16:31:36.000Z","date":"2018-06-06","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the award will vest on June 6, 2019, one-third will vest on June 6, 2020, and the award will be fully vested on June 6, 2021."}],"balance_after":250000,"derivative":{"exercise_price":1.71,"exercise_date":"2019-06-06","expiration_date":"2028-06-06","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001493152-18-008407","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100397/000149315218008407/form4.xml","form_type":"4"}}]}